1 優秀醫療投資者電話會議 2022年10月26日 2022年第三季度業績 弗雷德·蘭普普洛斯 董事長兼首席執行官 勞爾·帕拉 首席財務官

2與歷史事實陳述不同的前瞻性STATEMENTS Thispresentationandanyaccompanyingmanagementcommentaryinclude“forward-lookingstatements，”asdefinedwithinapplicablesecuritieslawsandregulations.Allstatementsinthis presentation，警示陳述是“前瞻性陳述”，包括但不限於有關業績預測計劃、淨銷售額、淨收益(公認會計原則和非公認會計原則)、營業收入和利潤率(公認會計原則和非公認會計原則)、毛利和利潤率(公認會計原則和非公認會計原則)、毛利和利潤率(公認會計原則和非公認會計原則)、盈利(公認會計原則和非公認會計原則)、自由現金流量、財務 措施、futuregrowthandprofitexpectationsorforecastedeconomicconditions，或通過Merit’sFoundationsforGrowthProgramorother expensereductioninitiatives，orthedevelopmentorcommercializationofnewproducts，areforward-lookingstatementswithinthemeaningofSection27AoftheSecuritiesActof1933，實現和實現的財務 措施、經修訂的andSection21EoftheSecuritiesExchangeActof1934，、andaresubjecttorisksanduncertaintiessuchasthosedescribedinMerit’sAnnualReportonForm10-Kforthe yearendedDecember31，。2021(the“2021AnnualReport”)andotherfilingswiththeSEC.SuchrisksanduncertaintiesincludeinherentrisksanduncertaintiesrelatingtoMerit’sinternalmodelsor theprojectionsinthisrelease；價值供應鏈中的中斷、manufacturingorsterilizationprocesses；reducedavailabilityof，和與commoditycomponents； adversechangesinfreight，shippingandtransportationexpenses；risksrelatingtoMerit’spotentialinabilitytosuccessfullymanagegrowththroughacquisitionsgenerally，includingtheinabilityto effectivelyintegrateacquiredoperationsorproductsorcommercializetechnologydevelopedinternallyoracquiredthroughcompleted，proposedorfuturetransactions；negativechangesin economicandindustryconditionsintheUnitedStatesorothercountries相關的價格增加, Includinginflation；fluctuationsininterestorforeigncurrencyexchangerates；risksanduncertaintiesassociatedwith Merit’sinformationtechnologysystems，includingthepotentialforbreachesofsecurityandevolvingregulationsregardingprivacyanddataprotection；governmentalscrutinyandregulationofthe medicaldeviceindustry，包括政府查詢、investigationsandproceedingsinvolvingMerit；litigationandotherjudicialproceedingsaffectingMerit；restrictionsonMerit’sliquidityor businessoperationsresultingfromitsdebtagreements；infringementofMerit’stechnologyortheassertionthatMerit’stechnologyinfringestherightsofotherparties；productrecallsandproduct liabilityclaims；changesincustomerpurchasingpatternsorthemixofproductsMeritsells；difficulties，延遲和與開發相關的支出，testingandregulatoryapprovalor clearanceofMerit’sproducts，includingthepursuitofapprovalsundertheE.U.MedicalDeviceRegulation，andrisksthatsuchproductsmaynotbedevelopedsuccessfullyorapprovedfor commercialuse；thepotentialoffines，penaltiesorotheradverseconsequencesifMerit’semployeesoragentsviolatetheU.S.ForeignCorruptPracticesActorotherlawsorregulations；lawsand regulationstargetingfraudandabuseinthehealthcareindustry；potentialforsignificantadversechangesingoverningregulations，includingreformstotheproceduresforapprovalorclearanceof Merit’sproductsbytheU.S.Food&DrugAdministrationorcomparableregulatoryauthoritiesinotherjurisdictions；changesintaxlawsandregulationsintheUnitedStatesorothercountries； terminationofrelationshipswithMerit’ssuppliers, Orfailureofsuchsupplierstoperform；risksanduncertaintiesassociatedwiththeCOVID-19pandemicandMerit’sresponsethereto； concentrationofasubstantialportionofMerit’srevenuesamongafewproductsandprocedures；developmentofnewproductsandtechnologythatcouldrenderMerit’sexistingorfuture productsobsolete；marketacceptanceofnewproducts；volatilityinthemarketpriceofMerit’scommonstock；modificationorlimitationofgovernmentalorprivateinsurancereimbursement policies；changesinhealthcarepoliciesormarketsrelatedtohealthcarereforminitiatives；failuretocomplywithapplicableenvironmentallaws；changesinkeypersonnel；workstoppageor transportationrisks；failuretointroduceproductsinatimelyfashion；priceandproductcompetition；availabilityoflaborandmaterials；fluctuationsinandobsolescenceofinventory；andother factorsreferencedinthe2021AnnualReportandothermaterialsfiledwiththeSEC. Allsubsequentforward-lookingstatementsattributabletoMeritorpersonsactingonitsbehalfareexpresslyqualifiedintheirentiretybythesecautionarystatements.Actualresultswilllikely differ，和可能在實質上不同，fromanticipatedresults.Financialestimatesaresubjecttochangeandarenotintendedtoberelieduponaspredictionsoffutureoperatingresults.Those estimatesandallotherforward-lookingstatementsincludedinthisdocumentaremadeonlyasofthedateofthisdocument，和其他適用法律所要求的其他概念，Meritassumesno obligationtoupdateordiscloserevisionstoestimatesandallotherforward-lookingstatements. 2

因此，3 NON-GAAPFINANCIALMEASURES AlthoughMerit’sfinancialstatementsarepreparedinaccordancewithaccountingprinciplesgenerallyacceptedintheUnitedStatesof America(“GAAP”)，Merit’smanagementbelievesthatcertainnon-GAAPfinancialmeasuresprovideinvestorswithusefulinformation regardingtheunderlyingbusinesstrendsandperformanceofMerit’songoingoperationsandcanbeusefulforperiod-over-period comparisonsofsuchoperations.Certainfinancialmeasuresincludedinthispresentation，orwhichmaybereferencedin management’sdiscussionofMerit’shistoricalandfutureoperationsandfinancialresults，havenotbeencalculatedinaccordancewith GAAP，和arereferencedasnon-GAAPfinancialmeasures.Readersshouldconsidernon-GAAPmeasuresusedinthis presentationinadditionto，不是financialreportingmeasurespreparedinaccordancewithGAAP.Thesenon-GAAP financialmeasuresgenerallyexcludesome，的替代品，而不是itemsthatmayaffectMerit‘snetincome.Inaddition，theyaresubjectto inherentlimitationsastheyreflecttheexerciseofjudgmentbymanagementaboutwhichitemsareexcluded.Additionally，non-GAAP financialmeasuresusedinthispresentationmaynotbecomparablewithsimilarlytitledmeasuresofothercompanies.Meriturges readerstoreviewthereconciliationsofitsnon-GAAPfinancialmeasurestothecomparableGAAPfinancialmeasures，Andnottorely onanysinglefinancialmeasuretoevaluateMerit’sbusinessorresultsofoperations.Pleasereferto“NotestoNon-GAAPFinancial Measures”attheendofthesematerialsformoreinformation. TRADEMARKS Unlessnotedotherwise，trademarksusedinthispresentationarethepropertyofMeritMedicalSystems，Inc.，intheUnitedStatesand otherjurisdictions. 3

4 第三季度2022Q3 2021YTD 2022YTD 2021 Revenue $287.2M$267.0M$857.6M$796.3M Gross利潤率 44.8%45.1%44.8%44.8% 營業利潤率 6.5%6.0%6.7%4.9% 每Income $15.3M$12.0M$41.1M$27.8M Earnings淨Share $0.27$0.21$0.71$0.49 FinancialSummary GAAP 4

5 第三季度2022Q3 2021YTD 2022YTD 2021 收入 (不變貨幣，Organic) † $295.2M$267.0M$873.3M$796.3M Gross利潤率 48.4%49.1%48.5%49.0% 營業利潤率 16.1%14.8%16.7%15.6% 每Income $37.0M$30.2M$109.7M$95.4M Earnings淨Share $0.64$0.52$1.91$1.67 FinancialSummary Non-GAAP* 5 *有關本演示文稿中使用的非公認會計準則計量的其他信息，請參閲下面的“非公認會計準則財務計量説明”。 † 非公認會計準則財務計量，代表不變的貨幣收入，有機。

6 收入明細-第三季度 區域第三季度2022Q3 2021$Change%ChangeCC%Change* U.S. $164,571$151,505$13,0668.6%6.6% APAC60,17556,9503,2255.7%13.7% EMEA52,06049,7332,3274.7%17.3% Rest of World10,3698,8331,53617.4%18.8% Total International 122,604115,5167,088 6.1%15.6% Total $287,175$267,021$20,1547.5%10.5% 6 *非公認會計準則財務指標，指按不變貨幣(“CC”)計算的收入增長。有關本演示文稿中使用的非GAAP衡量標準的其他信息，請參閲下面的“非GAAP財務衡量標準附註”。 單位為千，百分比除外

7 收入明細-YTD 區域YTD 2022YTD 2021$Change%ChangeCC%Change* U.S. $482,237$451,648$30,5896.8%5.4% APAC182,656169,61813,0387.7%12.3% EMEA160,743152,0688,6755.7%15.0% Rest of World31,93022,9259,00539.3%38.6% Total International 375,329344,61130,718 8.9%15.2% Total $857,566$796,259$61,3077.7%9.7% 7 *非公認會計準則財務指標，指按不變貨幣(“CC”)計算的收入增長。有關本演示文稿中使用的非GAAP衡量標準的其他信息，請參閲下面的“非GAAP財務衡量標準附註”。 單位為千，百分比除外

8 財務指標 指標第三季度2022Q3 2021YTD 2022YTD 2021 折舊和攤銷$20.4M$208M$6130萬$6320萬 股票補償(基於業績)1.4M1.6M4.4M4.0M 股票補償(非performance-based)3.2M3.2M9.3M7.6M Operating現金流量35.5M25.0M86.3M101.4M 資本支出-財產和設備15.8M6.8M32.5M19.6M 8

9 *有關本演示文稿中使用的非公認會計準則財務指標的更多信息，請參閲下面的“非公認會計準則財務指標説明”。 截至2022年12月31日的年度，Merit的財務指導會受到本演示文稿以及Merit提交給美國證券交易委員會(“美國證券交易委員會”)的文件中確定的風險和不確定性的影響。請參閲“有關前瞻性陳述的警示聲明。” 財務指標修訂指南先前指引 淨銷售額11.45億至11.151億美元 11.23億至11.35億美元 淨收益6,480萬至6,830萬美元6,240萬至6,830萬美元 每股收益 (GAAP) 1.13至1.19美元1.08至1.18美元 淨收益 (非GAAP)* 146美元90萬美元至1.504億美元1.396億美元至1.455億美元 每股收益 (非公認會計準則)* 2.55美元至2.61美元2.42美元至2.52美元 更新後的2022年財務指引

10 附錄 10

11 NotestoNon-GAAPFinancialMeasures Foradditionaldetails，pleaseseetheaccompanyingpressreleaseandforward-lookingstatementdisclosure. ThesepresentationmaterialsandassociatedcommentaryfromMerit’smanagement，以及今天發佈的新聞稿，使用非GAAP財務指標，including： •constantcurrencyrevenue； •constantcurrencyrevenue，organic； •non-GAAPgrossprofitandmargin； •non-GAAPoperatingincomeandmargin； •non-GAAPnetincome； •non-GAAPearningspershare；And •freecashflow. Merit’smanagementteamusesthesenon-GAAPfinancialmeasurestoevaluateMerit’sprofitabilityandefficiency，tocompareoperatingandfinancialresultstopriorperiods，to evaluatechangesintheresultsofitsoperatingsegments，andtomeasureandallocatefinancialresourcesinternally.However，Merit’smanagementdoesnotconsidersuchnon- GAAPmeasuresinisolationorasanalternativetomeasuresdeterminedinaccordancewithGAAP. Readersshouldconsidernon-GAAPmeasuresusedinthispresentationinadditionto，不是financialreportingmeasurespreparedinaccordancewithGAAP.These non-GAAPfinancialmeasuresgenerallyexcludesome，的替代品，但不是所有的，itemsthatmayaffectMerit’snetincome.Inaddition，theyaresubjecttoinherentlimitationsastheyreflectthe exerciseofjudgmentbymanagementaboutwhichitemsareexcluded.Meritbelievesitisusefultoexcludesuchitemsinthecalculationofnon-GAAPearningspershare，非GAAP總收入和利潤，非GAAP運營收入和利潤，以及非GAAP淨收入(每個案例，asfurtherillustratedinthereconciliationtablesbelow)because suchamountsinanyspecificperiodmaynotdirectlycorrelatetotheunderlyingperformanceofMerit’sbusinessoperationsandcanvarysignificantlybetweenperiodsasaresult offactorssuchasacquisitionorotherextraordinarytransactions，non-cashexpensesrelatedtoamortizationorwrite-offofpreviouslyacquiredtangibleandintangibleassets， 支出, Expensesresultingfromnon-ordinarycourselitigationoradministrativeproceedingsandresultingsettlements，公司轉換費用， governmentalproceedingsorchangesintaxorindustryregulations，在處置某些資產上的損失，anddebtissuancecosts.Meritmayincursimilartypesofexpenses inthefuture，andthenon-GAAPfinancialinformationincludedinthispresentationshouldnotbeviewedasastatementorindicationthatthesetypesofexpenseswillnotrecur. Additionally，thenon-GAAPfinancialmeasuresusedinthispresentationmaynotbecomparablewithsimilarlytitledmeasuresofothercompanies.Meriturgesinvestorsand potentialinvestorstoreviewthereconciliationsofitsnon-GAAPfinancialmeasurestothecomparableGAAPfinancialmeasures，andnottorelyonanysinglefinancialmeasureto evaluateMerit’sbusinessorresultsofoperations.

12 NotestoNon-GAAPFinancialMeasures(cont.) ConstantCurrencyRevenue Merit’sconstantcurrencyrevenueispreparedbyconvertingthecurrent-periodreportedrevenueofsubsidiarieswhosefunctionalcurrencyisacurrencyotherthantheU.S.dollarat theapplicableforeignexchangeratesineffectduringthecomparableprior-yearperiod，andadjustingfortheeffectsofhedgingtransactionsonreportedrevenue，whicharerecorded intheU.S.Theconstantcurrencyrevenueadjustmentsof$8.0millionand$15.8milliontoreportedrevenueforthethreeandnine-monthperiodsendedSeptember30,2022，were calculatedusingtheapplicableaverageforeignexchangeratesforthethreeandnine-monthperiodsendedSeptember30,2021。 恆定當前收入，有機 固定現貨收入，有機，定義，按優先或財政期間，asGAAPrevenue.Withrespecttocurrentfiscalyearperiods，恆定貨幣收入，有機，isdefinedasconstantcurrencyrevenue(asdefinedabove)，lessrevenuefromcertainacquisitions.Forthethreeandnine-monthperiodsendedSeptember30,2022， therewerenorevenuesfromacquisitionsexcludedinthecalculationofMerit’sconstantcurrencyrevenue，Organic. Non-GAAPGrossProfitandMargin Non-GAAPgrossprofitiscalculatedbyreducingGAAPcostofsalesbyamountsrecordedforamortizationofintangibleassetsandcertaininventorywrite-offs.Non-GAAPgross marginiscalculatedbydividingnon-GAAPgrossprofitbyreportednetsales. Non-GAAPOperatingIncomeandMargin Non-GAAPoperatingincomeiscalculatedbyadjustingGAAPoperatingincomeforcertainitemswhicharedeemedbyMerit’smanagementtobeoutsideofcoreoperationsand varyinamountandfrequencyamongperiods，suchasexpensesrelatedtoacquisitionsorotherextraordinarytransactions，non-cashexpensesrelatedtoamortizationorwrite-offof previouslyacquiredtangibleandintangibleassets，確定的費用、基於業績的股票薪酬費用、公司轉換費用, Expenses resultingfromnon-ordinarycourselitigationoradministrativeproceedingsandresultingsettlements，governmentalproceedingsorchangesinindustryregulations，aswellasother itemsreferencedinthetablesbelow.Non-GAAPoperatingmarginiscalculatedbydividingnon-GAAPoperatingincomebyreportednetsales.

13 NotestoNon-GAAPFinancialMeasures(cont.) Non-GAAPNetIncome Non-GAAPnetincomeiscalculatedbyadjustingGAAPnetincomefortheitemssetforthinthedefinitionofnon-GAAPoperatingincomeabove，aswellasforexpensesrelatedto debtissuancecosts，因處置某些資產而虧損，税制變更，分別aswellasotheritemssetforthinthetablesbelow. Non-GAAPEPS Non-GAAPEPSisdefinedasnon-GAAPnetincomedividedbythedilutedsharesoutstandingforthecorrespondingperiod. FreeCashFlow FreecashflowisdefinedascashflowfromoperationscalculatedinaccordancewithGAAP，lesscapitalexpendituresforpropertyandequipmentcalculatedinaccordancewith GAAP，assetforthintheconsolidatedstatementofcashflows. OtherNon-GAAPFinancialMeasureReconciliation Thefollowingtablessetforthsupplementalfinancialdataandcorrespondingreconciliationsofnon-GAAPfinancialmeasurestoMerit’scorrespondingfinancialmeasuresprepared inaccordancewithGAAP，個別，forthethreeandnine-monthperiodsendedSeptember30,2022and2021.Thenon-GAAPincomeadjustmentsreferencedinthefollowing tablesdonotreflectnon-performance-basedstockcompensationexpenseof$3.2millionand$3.2millionforthethree-monthperiodsendedSeptember30,2022and2021， ，and$9.3millionand$7.6millionforthenine-monthperiodsendedSeptember30,2022and2021，。

14 ReconciliationofGAAPNetIncometoNon-GAAPNetIncome (Unaudited;inthousandsexceptpershareamounts) Note: Certain per share impacts may not sum to totals due to rounding. GAAP net income$17,602 $(2,330) $15,272 $0.27 $14,177 $(2,210) $11,967 $0.21 Non-GAAP adjustments: Cost of Sales Amortization of intangibles 10,487 (2,571) 7,916 0.14 10,573 (2,626) 7,947 0.14 Operating Expenses Contingent consideration expense 915 — 915 0.02 1,115 (16) 1,099 0.02 Amortization of intangibles 1,554 (384) 1,170 0.02 1,793 (449) 1,344 0.02 Performance-based share-based compensation (b) 1,353 (70) 1,283 0.02 1,639 (207) 1,432 0.02 Corporate transformation and restructuring (c) 8,535 (1,796) 6,739 0.12 4,282 (1,061) 3,221 0.06 Acquisition-related667 (163) 504 0.01 2,866 (711) 2,155 0.04 Medical Device Regulation expenses (d) 3,873 (948) 2,925 0.05 1,129 (280) 849 0.01 Other (e) 116 (28) 88 0.00 159 (78) 81 0.00 Other (Income) Expense Amortization of long-term debt issuance costs 151 (37) 114 0.00 151 (37) 114 0.00 Loss on disposal of business unit135 (32) 103 0.00 — — — — Non-GAAP net income $45,388 $(8,359) $37,029 $0.64 $37,884 $(7,675) $30,209 $0.52 Diluted shares 57,586 57,549 Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited, in thousands except per share amounts) Three Months Ended Three Months Ended September 30, 2022September 30, 2021 After-TaxPer Share Impact Pre-TaxTax ImpactAfter-TaxPer Share ImpactPre-TaxTax Impact

15 ReconciliationofGAAPNetIncometoNon-GAAPNetIncome (Unaudited；(以千股為單位) 注意：由於四捨五入的原因，某些每股影響的總和可能不是總計。 GAAP淨收入 $ 52,474 $ (11,359) $ 41,115 $ 0.71 $ 33,736 $ (5，895) $ 27，$ $ 0.49 非公認會計準則adjustments： Cost of Sales {br 無形資產攤銷 31，539 (7,733) 23,806 0.41 31,884 (7,918) 23，966 0.42 庫存核銷(a) — — — — 1,620 (202) 1.418 0.02 運營Expenses Contingent對價費用 4,702 (17) 4,685 0.08 3，322 (2) 3,320 0.06 減值費用 1,672 (318) 1,354 0.02 4，283 (481) 3,802 0.07 無形資產攤銷 4,749 (1,176) 3,573 0.06 5,397 (1，045 0.07 Performance-based股票薪酬(B) 4,354 (413) 3,941 0.07 3,998 (494) 3，504 0.06 企業轉型重組(C) 20,432 (4,702) 15,730 0.27 17,044 (4,223) 12，821 0.22 Acquisition-related 1, 901 (465) 1,436 0.02 8,475 (2,101) 6,374 0.11 醫療器械規費(D) 8,451 (2，069) 6,382 0.11 2,523 (625) 1,898 0.03 其他(E) 7,845 (1,863) 5，982 0.10 6,534 (468) 6，066 0.11 其他(收入)支出 長期債務發行costs 453 (111) 342 0.01 453 (112) 341攤銷 0.01 業務部門處置虧損 1，390 (32) 1,358 0.02 — — — — Non-GAAP淨收入 $139,962 $(30,258) $109，704 $1.91 $119,269 $(23,873) $95,396 $1.67 稀釋股份 57,573 57，274 每股税後影響 税前 每股税後影響 税前 每股税後影響 截至9個月 截至2021年9月30日的9個月 2021年9月30日

16 ReconciliationofGAAPOperatingIncometoNon-GAAPOperatingIncome (Unaudited;inthousandsexceptpercentages) Note: Certain percentages may not sum to totals due to rounding. Net Sales as Reported $287,175 $267,021 $857,566 $796,259 GAAP Operating Income 18,657 6.5 %15,931 6.0 %57,146 6.7 %39,020 4.9 % Cost of Sales Amortization of intangibles 10,487 3.7 %10,573 4.0 %31,539 3.7 %31,884 4.0 % Inventory write-off (a)— — — — — — 1,620 0.2 % Operating Expenses Contingent consideration expense 915 0.3 %1,115 0.4 %4,702 0.5 %3,322 0.4 % Impairment charges — — — — 1,672 0.2 %4,283 0.5 % Amortization of intangibles 1,554 0.5 %1,793 0.7 %4,749 0.6 %5,397 0.7 % Performance-based share-based compensation (b) 1,353 0.5 %1,639 0.6 %4,354 0.5 %3,998 0.5 % Corporate transformation and restructuring (c) 8,535 3.0 %4,282 1.6 %20,432 2.4 %17,044 2.1 % Acquisition-related667 0.2 %2,866 1.1 %1,901 0.2 %8,475 1.1 % Medical Device Regulation expenses (d) 3,873 1.3 %1,129 0.4 %8,451 1.0 %2,523 0.3 % Other (e)116 0.0 %159 0.1 %7,845 0.9 %6,534 0.8 % Non-GAAP Operating Income $46,157 16.1%$39,487 14.8%$142,791 16.7%$124,100 15.6% Amounts% Sales Amounts% SalesAmounts% SalesAmounts% Sales Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, 2022September 30, 2021September 30, 2022September 30, 2021

17 Footnotes to Reconciliations of GAAP Net Income to Non-GAAP Net Income and GAAP Operating Income to Non-GAAP Operating Income a)Representsthewrite-offofinventoryrelatedtothedivestitureorexitofcertainbusinessesorproductlines. b)Representsperformance-basedshare-basedcompensationexpense,includingstock-settledandcash-settledawards. c)IncludesconsultingexpensesrelatedtotheFoundationsforGrowthProgramandothertransformationcosts,including severancerelatedtocorporateinitiatives. d)RepresentsincrementalexpensesincurredtocomplywiththeE.U.MedicalDeviceRegulation(“MDR”). e)Thethree-monthperiodendedSeptember30,2022includescoststocomplywithMerit’scorporateintegrityagreementwith theU.S.DepartmentofJustice(the“DOJ”).The2022year-to-dateperiodalsoincludesacquiredin-processresearchand developmentchargesof$6.7millionandlegalcostsassociatedwithashareholderderivativeproceeding.The2021periods includeaccruedcontractterminationcostsof$6.1milliontorenegotiatecertaintermsofanacquisitionagreementandcosts tocomplywithMerit’scorporateintegrityagreementwiththeDOJ.

18 Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP) (Unaudited; in thousands except percentages) (a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this presentation entitled “Notes to Non-GAAP Financial Measures.” Three Months Ended Nine Months Ended September 30, September 30, % Change 2022 2021 % Change 2022 2021 Reported Revenue 7.5 % $ 287,175 $ 267,021 7.7 % $ 857,566 $ 796,259 Add: Impact of foreign exchange 7,975 — 15,763 — Constant Currency Revenue (a) 10.5 % $ 295,150 $ 267,021 9.7 % $ 873,329 $ 796,259 Less: Revenue from certain acquisitions — — — — Constant Currency Revenue, Organic (a) 10.5 % $ 295,150 $ 267,021 9.7 % $ 873,329 $ 796,259

19 ReconciliationofGAAPGrossMargintoNon-GAAPGrossMargin (Unaudited;asapercentageofreportedrevenue) Note: Certain percentages may not sum to totals due to rounding. a) Represents the write-off of inventory related to the divestiture or exit of certain businesses or product lines. Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Reported Gross Margin 44.8 % 45.1 % 44.8 % 44.8 % Add back impact of: Amortization of intangibles 3.7 % 4.0 % 3.7 % 4.0 % Inventory write - off (a) — — % — % 0.2 % Non - GAAP Gross Margin 48.4 % 49.1 % 48.5 % 49.0 %